(CercleFinance.com) – The biotechnology company Novavax announces the launch of a phase 2 trial for its candidate vaccines against influenza alone on the one hand, and combinations against Covid-19 and influenza on the other.
The trial will aim to enroll a total of approximately 2,300 participants and will assess the safety as well as the efficacy (immunogenicity) of different formulations of these candidate vaccines in adults aged 50 to 80 years. The first results are expected around mid-2023.
“We are encouraged by the positive results reported earlier this year from our Phase 1/2 trial, the first of its kind to evaluate a combination vaccine against Covid-19 and influenza,” CEO Stanley Erck said. .
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
